24 research outputs found

    Temperature and physical property control for polymerization reactors

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(๋ฐ•์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :ํ™”ํ•™๊ณตํ•™๊ณผ,1996.Docto

    Construction of efficient expression vector system using cis-acting elements for Lactococcus lactis

    Get PDF
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ๋†์ƒ๋ช…๊ณตํ•™๋ถ€, 2014. 2. ์ตœ์œค์žฌ.Many approaches have been attempted to improve the heterologous protein in various bacteria. Specifically, the plasmid-based expression system has been used to achieve the recombinant protein production as an easy and useful tool to manipulate. There are three strategies to improve the expression level of recombinant protein. Such as 1) introduction of high copies plasmid-based expression vector system, 2) construction of gene multimerization cassette as a insert and ligation with the backbone vector, and 3) search of new strong promoter. However there are several limitations for these strategies in that it is hard to replicate the DNA, is too large to transformed which causes genetic instability, and is hard to predict promoter strength. In this study, I modified the promoter region and tested on the promoter strength. In addition, I tried to introduce another cis-acting elements such as a transcriptional terminator and RBS (ribosome binding site) to improve the expression of recombinant protein. Lactococcus lactis subsp. lactis IL1403 is widely used in the dairy and animal industries, and it is also studied for a live oral vaccine product to elicit mucosal immune response. The translational elongation factor Tu (tuf) gene is a house-keeping gene, and tuf promoter is characterized as a strong promoter in IL1403. In this study, tuf promoter was modified to test the efficiency of protein expression using the luciferase gene as a reporter. Firstly two terminators, TrrnB and TpepN were tested for the luciferase gene expression efficiency. TpepN terminator showed better performance in luciferase expression. Next, series of tuf promoter modification were attempted. In bacteria, RNA polymerases and several sigma factors recognized and recruited approximately -35 and -10 region upstream from the transcription start site. The core region including -35 and -10 hexamers in tuf promoter (119 bp) was amplified and series of modified tuf promoters were constructed using PCR with partial complementary reverse primer. There PCR products (#1) were cloned into the promoterless pIL.Ptuf.Luc(X) vector. Luciferase activity of t2, t4, t6 and t7 were higher than control tuf promoter. Especially t2 and t4 showed better performance, thus selected for next experiment. It is well known that the sequence between RBS and start codon (ATG) are important for protein translation efficiency. Thus, I modified original sequence of this region, 'CATTTTTCAT' to 'AATTTTTAAA' to give more AT-rich. This modification was combined with selected modified tuf promoter to give a series of new tuf promoter cassette. The transformed IL1403s containing modified promoter (#2) were assayed for luciferase activity. Derivative of t2 and t4, t2-1 and t4-1 showed better performance. Combined all the modified clones, luciferase activity was compared. t4-1 showed much higher activity compared to the t4, indicating the sequence between RBS and start codon is important for protein expression. To confirm this results, luciferase expression was analyzed on SDS-PAGE and western blot assay. Luciferase bands (61 kDa) was not detectable in SDS-PAGE, but in western blot, clones with t2, t4, t4-1 showed stronger signal compared to original tuf one. In conclusion, this study revealed that introduction of modified strong promoter and additional cis-acting elements can improve the protein expression in IL1403. And this strategy has a prospect to improve recombinant protein expression. Since pIL252 is a low copy plasmid-based expression system, high copies-based plasmids are needed to increase recombinant protein expression.Summary I Contents IV List of Tables and Figures VII List of Abbreviations Iโ…ฉ I. Introduction 1 II. Review of Literature 3 1. Lactic Acid Bacteria (LAB) 3 1) Lactic Acid Bacteria 3 2) LAB as probiotics 4 3) Lactococcus lactis 7 2. Recombinant protein expression 8 1) Plasmid-based expression system 8 2) Recombinant protein expression strategy 8 3. Cis-acting elements 9 1) Promoter 9 2) Cis-acting elements 10 4. The tuf gene 11 III. Materials and Methods 12 1. Bacterial cultivation 12 1) Culture medium 12 2) Cultivation and harvest of bacterial cells 12 2. Transformation of bacteria 13 1) Preparation of IL1403 competent cells 13 2) Transformation of bacterial cells 13 3. DNA works 14 1) Plasmid 14 2) Preparation of plasmid DNA 14 3) Enzyme treatment 17 4) PCR reaction 17 5) PCR purification 17 6) Analysis of nucleotide sequences 18 4. Luciferase assay 20 1) Growth phase-dependent luciferase expression 20 2) Detection of chemiluminescence 20 5. Protein works 21 1) Protein extraction from LAB cells 21 2) Quantification of proteins 21 3) SDS-PAGE and western blot assay 21 4) Intensity measurement of protein bands 22 6. In vitro characterization 23 1) Growth of LAB cells 23 2) pH measurement of LAB cultures 23 IV. Results and Discussion 24 1. Introduction of reporter gene with terminator 24 1) Cloning of luciferase gene 24 2) Vector construction 25 2. Validation of reporter gene and terminator 26 1) Growth characteristics 26 2) Luciferase assay 27 3. Modification of tuf promoter (#1) 28 1) Amplification of short fragments 28 2) Construction of repeated fragments 29 3) Elongation of ribosome binding site (RBS) and enzyme sites 30 4) Introduction of modified promoter (#1) 31 4. Modified promoter (#1) activity assay 35 1) Growth characteristics (#1) 35 2) Luciferase assay (#1) 35 5. Construction of remodified promoter (#2) 37 1) Core promoter cassette preparation from modified promoter (#1) 37 2) Elongation of RBS and modified downstream sequences 38 6. Remodified promoter (#2) activity assay 41 1) Luciferase assay (#2) 41 2) Final luciferase assay 42 7. Confirmation of Protein expression 44 1) SDS-PAGE and western blot assay 44 V. Literature Cited 46 VI. Summary in Korean 58 VII. Acknowledgement 61Maste

    ๋‹ค๊ณต์„ฑ๋ฌผ์งˆ์—์„œ์˜ ์ž์—ฐ๋Œ€๋ฅ˜ํ˜„์ƒ์— ๋Œ€ํ•œ ์—ด์—ญํ•™์  ๊ตญ์†Œํ‰ํ˜•์ƒํƒœ ๊ฐ€์ •์˜ ๊ณ ์ฐฐ

    No full text
    ํ•™์œ„๋…ผ๋ฌธ(์„์‚ฌ)--์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› :๊ธฐ๊ณ„๊ณตํ•™๊ณผ,2000.Maste

    (The) study of the actual condition of visiting nurse projects in public health centers in Seoul

    No full text
    ์ง€์—ญ์‚ฌํšŒ ๊ฐ„ํ˜ธํ•™๊ณผ/์„์‚ฌ[ํ•œ๊ธ€] ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์˜ ๊ธฐ๋ณธ ์ •์ฑ…๋ฐฉํ–ฅ์€ ๊ตญ๋ฏผ ๋ˆ„๊ตฌ๋‚˜ ํฌ๊ด„์ ์ธ ๋ณด๊ฑด์˜๋ฃŒ์˜ ํ˜•ํ‰์„ฑ๊ณผ ๋™๋“ฑํ•œ ์ ‘๊ทผ๋„๋ฅผ ์œ ์ง€ํ•˜์—ฌ ์งˆ์ ์ธ ์‚ถ์„ ์œ ์ง€ํ•˜๊ฒŒ ํ•˜๋ฉฐ ๋ณต์ง€์‚ฌํšŒ๋ฅผ ์‹คํ˜„ํ•˜๊ณ ์ž ํ•จ์ด๋‹ค. ๋ณธ ์—ฐ๊ตฌ๋Š” ๋ณด๊ฑด์†Œ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์˜ ์กฐ์ง, ์ธ๋ ฅ, ์˜ˆ์‚ฐ, ์ค€๋น„๋„, ์—…๋ฌด๋ฅผ ์‚ดํŽด๋ณด๊ณ  ์ด๋ฅผ ๊ธฐ์ดˆ๋กœ ํšจ์œจ์ ์ธ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์„ ์ œ์‹œํ•˜๊ณ ์ž ์‹œ๋„ํ•˜์˜€๋‹ค. ์—ฐ๊ตฌ๋ฐฉ๋ฒ•์œผ๋กœ๋Š” ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์˜ ๋ฐฉํ–ฅ์„ค์ •์— ๊ด€ํ•œ ๋ฌธํ—Œ๊ณ ์ฐฐ๊ณผ ๊ตญ๋‚ด ๊ธฐ๊ด€์˜ ํ†ต๊ณ„์ž๋ฃŒ๋ฅผ ์‚ฌ์šฉํ•˜์˜€๊ณ  ๋˜ํ•œ ์„œ์šธ์‹œ 25๊ฐœ ๋ณด๊ฑด์†Œ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—… ๋‹ด๋‹น์ž 221๋ช…์„ ๋ชจ์ง‘๋‹จ์œผ๋กœ ํ•˜์—ฌ ์šฐํŽธ์„ ์ด์šฉํ•˜์—ฌ ์„ค๋ฌธ์กฐ์‚ฌํ•˜์˜€๋‹ค. ์ž๋ฃŒ์ˆ˜์ง‘ ๊ธฐ๊ฐ„์€ 1996๋…„ 11์›” 2์ผ ๋ถ€ํ„ฐ 1996๋…„ 11์›” 16์ผ๊นŒ์ง€์˜€์œผ๋ฉฐ ๋ถ„์„์— ์‚ฌ์šฉ๋œ ์—ฐ๊ตฌ๋Œ€์ƒ์ž ์ˆ˜๋Š” 23๊ฐœ ๋ณด๊ฑด์†Œ 184๋ช…์ด์—ˆ๋‹ค. ๋ณธ ์—ฐ๊ตฌ์˜ ์ฃผ์š” ๊ฒฐ๊ณผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™๋‹ค. 1. ์กฐ์ง ํ˜„ํ™ฉ ์„œ์šธ์‹œ๋Š” ์ด 25๊ฐœ์˜ ๋ณด๊ฑด์†Œ๊ฐ€ ์žˆ์œผ๋ฉฐ ํฌ๊ฒŒ ๋‚˜๋ˆ„์–ด ์ง€์—ญ๋ณด๊ฑด๊ณผ๋ฅผ ๋‘๊ณ  ๋…๋ฆฝ์ ์œผ๋กœ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์„ ๋‹ด๋‹นํ•˜๋Š” 8๊ฐœ๊ตฌ ๋ณด๊ฑด์†Œ์™€ ๊ทธ๋ ‡์ง€ ์•Š์€ 17๊ฐœ๊ตฌ ๋ณด๊ฑด์†Œ๋กœ ๋‚˜๋ˆ„์–ด ์ง€๋ฉฐ ํ˜„์กด ์กฐ์ง์œผ๋กœ๋Š” ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์„ ์ˆ˜ํ–‰ํ•˜๋Š”๋ฐ ํ•œ๊ณ„๊ฐ€ ์žˆ๋‹ค๊ณ  ํ•  ์ˆ˜ ์žˆ๋‹ค. 2. ์ธ๋ ฅํ˜„ํ™ฉ ์„œ์šธ์‹œ ๋ณด๊ฑด์†Œ์˜ ํ˜„์›์€ 95๋…„ ํ˜„์žฌ ์ด 2,020๋ช…์ด๋ฉฐ ์ด์ค‘ ๊ฐ„ํ˜ธ์ง์ด 647๋ช…์œผ๋กœ 32%๋ฅผ ์ฐจ์ง€ํ•˜๊ณ  ์žˆ์œผ๋‚˜ ๊ทธ ์ง๊ธ‰์€ ์ƒ๋Œ€์ ์œผ๋กœ ๋‚ฎ์Œ์„ ์•Œ ์ˆ˜ ์žˆ๋‹ค. ๋ณธ ๋…ผ๋ฌธ์—์„œ ์กฐ์‚ฌํ•œ 184๋ช…์„ ๋Œ€์ƒ์œผ๋กœ ์‘๋‹ต์ž์˜ ์ผ๋ฐ˜์  ํŠน์„ฑ์„ ์‚ดํŽด ๋ณด๋ฉด ๋ณด๊ฑด๊ด€๋ฆฌ์ž๋Š”ํ‰๊ท  46.5์„ธ, ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ๋Š” ํ‰๊ท  35.7์„ธ๋กœ ๋‚˜ํƒ€๋‚ฌ์œผ๋ฉฐ ๊ต์œก์ˆ˜์ค€์€ ์ „๋ฌธ๋Œ€ ์กธ์—…์ž๊ฐ€ ๊ฐ€์žฅ ๋งŽ์€ ๋ถ€๋ถ„์„ ์ฐจ์ง€ํ•˜๊ณ  ์žˆ์—ˆ๋‹ค. ํŠน๋ณ„๊ต์œก๊ณผ์ •์ค‘ CPHN๊ณผ ๊ฐ€์ •๊ฐ„ํ˜ธ์‚ฌ ๊ต์œก์€ ๋Œ€๋ถ€๋ถ„์ด ์ด์ˆ˜ ํ•˜์ง€ ์•Š์€ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ์ด๋“ค์˜ ์ง๊ธ‰์€ ๋ณด๊ฑด๊ด€๋ฆฌ์ž๋Š” 6๊ธ‰, ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ๋Š” 8๊ธ‰์ด ๊ฐ€์žฅ ๋งŽ์€ ๊ฒƒ์œผ๋กœ ์กฐ์‚ฌ๋˜์—ˆ์œผ๋ฉฐ 5๊ธ‰ ์ด์ƒ ์‘๋‹ต์ž 6๋ช… ์ค‘ 2๋ช…๋งŒ ๊ฐ„ํ˜ธ์ง์œผ๋กœ ์กฐ์‚ฌ๋˜์–ด ์˜์‚ฌ๊ฒฐ์ •๊ถŒ์ด ๋ฏธ์•ฝํ•จ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ๋‹ค. ํ˜„๋ถ€์„œ ๊ทผ๋ฌด๊ธฐ๊ฐ„์€ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์˜ ๊ฒฝ์šฐ ํ‰๊ท  1.5๋…„์œผ๋กœ ์ด๋™์ด ์žฆ์Œ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ์œผ๋ฉฐ ์ž„์ƒ๊ฒฝ๋ ฅ์€ ํ‰๊ท  5๋…„ ์ด์ƒ์œผ๋กœ ์งˆ์  ์„œ๋น„์Šค์˜ ์ œ๊ณต์„ ์œ„ํ•ด ๋ฐ”๋žŒ์งํ•œ ๊ตฌ์„ฑ์ด๋ผ๊ณ  ๋ณผ ์ˆ˜ ์žˆ๋‹ค. 3. ์˜ˆ์‚ฐ ํ˜„ํ™ฉ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์˜ ์˜ˆ์‚ฐ์— ๋Œ€ํ•œ ๋งŒ์กฑ๋„๋Š” ์ „๋ฐ˜์ ์œผ๋กœ ๋‚ฎ์€ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์œผ๋ฉฐ ์ฐจ๋Ÿ‰์ง€์› ๋ฐ ์‹œ์„ค ๋ฐ ์žฅ๋น„์— ๋Œ€ํ•ด์„œ๋„ ๋ถˆ๋งŒ์กฑํ•˜๋‹ค๋Š” ์‘๋‹ต์ด ๋†’์•˜๋‹ค. ๋˜ํ•œ ์˜ˆ์‚ฐํŽธ์„ฑ์—์„œ ๋ณด๊ฑด๊ด€๋ฆฌ์ž๋Š” ์‹ ์ถ•์„ฑ ์žˆ๊ฒŒ ์˜ˆ์‚ฐ ํŽธ์„ฑ์ด ์ด๋ฃจ์–ด์ง„๋‹ค๊ณ  ์‘๋‹ตํ•œ ๋ฐ˜๋ฉด ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ๋Š” ์˜ˆ์‚ฐ ํŽธ์„ฑ์ด ์‹ ์ถ•์ ์ด ์ง€ ๋ชปํ•˜๋‹ค๊ณ  ์‘๋‹ตํ•˜์—ฌ ์ƒ๋ฐ˜๋œ ๊ฒฌํ•ด๋ฅผ ๋ณด์˜€๋‹ค. 4. ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ๋Œ€ํ•œ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์˜ ์ค€๋น„๋„ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ๋Œ€ํ•œ ์ค€๋น„๋„์—์„œ๋Š” ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ๋Œ€ํ•œ ๊ต์œก์˜ ๊ธฐํšŒ๊ฐ€ ๋ณด๋‹ค ํญ ๋„“๊ฒŒ ์ด๋ฃจ์–ด ์ ธ์•ผ ํ•จ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ์œผ๋ฉฐ ์ด๋“ค์ด ์›ํ•˜๋Š” ๊ต์œก๋ฐฉ๋ฒ•์œผ๋กœ๋Š” ๋ณด๊ฑด๊ด€๋ฆฌ์ž๋Š” ์„ธ๋ฏธ๋‚˜์™€ ๋‹จ๊ธฐ์—ฐ์ˆ˜๋ฅผ, ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ๋Š” ๋‹จ๊ธฐ์—ฐ์ˆ˜์™€ ์ •๊ทœ๋Œ€ํ•™ /๋Œ€ํ•™์›์„ ์„ ํ˜ธํ•˜๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. 5. ์—…๋ฌดํ˜„ํ™ฉ ์„œ์šธํŠน๋ณ„์‹œ์˜ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์€ ์ƒํ™œ๋ณดํ˜ธ๋Œ€์ƒ์ž์™€ ์ €์†Œ๋“ ์ฃผ๋ฏผ์„ ๋Œ€์ƒ์œผ๋กœ ํ™˜์ž๊ด€๋ฆฌ, ๊ฑด๊ฐ•๊ด€๋ฆฌ, ์—ฐ๊ณ„์ฒ˜๋ฆฌ, ์ˆœํšŒ์ง„๋ฃŒ, ๋ณด๊ฑด๊ต์œก์„ ํ•˜๊ณ  ์žˆ์—ˆ๋‹ค. ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์˜ ์—…๋ฌด ํ˜„ํ™ฉ์„ ์‚ดํŽด๋ณด๋ฉด ๋น„๊ต์  ์ž˜ ๋˜๊ณ  ์žˆ๋Š” ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ์œผ๋ฉฐ ํŠนํžˆ ํ™˜์ž์— ๋Œ€ํ•œ ์ถ”ํ›„๊ด€๋ฆฌ์™€ ์ฃผ๋ฏผ์„ ๋Œ€์ƒ์œผ๋กœ ํ•˜๋Š” ํŠน์ˆ˜์‚ฌ์—…์—์„œ ์ž˜๋˜๊ณ  ์žˆ๋‹ค๊ณ  ์‘๋‹ตํ•˜์˜€๋‹ค. ๊ทธ๋Ÿฌ๋‚˜ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ๋Œ€ํ•œ ์ฃผ๋ฏผ ์ฐธ์—ฌ, ํƒ€ ๊ธฐ๊ด€๊ณผ์˜ ์—ฐ๊ณ„๋ง ํ˜•์„ฑ, ์ „์‚ฐํ™”์—์„œ๋Š” ์›ํ™œํ•˜๊ฒŒ ์ด๋ฃจ์–ด์ง€๊ณ  ์žˆ์ง€ ์•Š๋‹ค๊ณ  ์‘๋‹ตํ•˜์—ฌ ๊ฐœ์„ ์ด ์š”๊ตฌ๋˜์—ˆ๋‹ค. 6. ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ์˜ํ–ฅ์„ ๋ฏธ์น˜๋Š” ์š”์ธ 1) ์ง€์—ญ๋ณด๊ฑด๊ณผ์˜ ์œ ๋ฌด์™€ ํƒ€ ์—…๋ฌด๋ณ‘ํ–‰๊ณผ์˜ ๊ด€๋ จ์„ฑ ์ง€์—ญ๋ณด๊ฑด๊ณผ๋Š” ์„œ์šธ์‹œ๊ฐ€ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์„ ์‹ค์‹œํ•˜๊ธฐ ์œ„ํ•œ ์ผํ™˜์œผ๋กœ ์กฐ์ง ๊ฐœํŽธํ•˜์—ฌ ์‹ ์„ค๋œ ๊ณผ๋กœ์„œ ์ง€์—ญ๋ณด๊ฑด๊ณผ๊ฐ€ ์—†๋Š” ๊ณณ์—์„œ ํƒ€ ์—…๋ฌด๋ฅผ ๋” ๋งŽ์ด ๋ณ‘ํ–‰ํ•˜๊ณ  ์žˆ๋Š”๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. 2) ๋ณด๊ฑด๊ด€๋ฆฌ์ž์˜ ๊ด€์‹ฌ๋„์™€ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…๊ณผ์˜ ๊ด€๋ จ์„ฑ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ๋Œ€ํ•œ ๋ณด๊ฑด๊ด€๋ฆฌ์ž์˜ ๊ด€์‹ฌ๋„๋Š” ๋†’์€ ๊ฒƒ์œผ๋กœ ๋‚˜ํƒ€๋‚ฌ๋‹ค. ๋˜ํ•œ ๋ณด๊ฑด๊ด€๋ฆฌ์ž์˜ ๊ด€์‹ฌ๋„๊ฐ€ ๋†’์„์ˆ˜๋ก ์˜ˆ์‚ฐ์— ๋Œ€ํ•œ ๋งŒ์กฑ์—ฌ๋ถ€, ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ๋Œ€ํ•œ ํ‰๊ฐ€, ์ฃผ๋ฏผ์„ ๋Œ€์ƒ์œผ๋กœ ํ•˜๋Š” ํŠน์ˆ˜์‚ฌ์—…์—์„œ ํ†ต๊ณ„ํ•™์ ์œผ๋กœ ์œ ์˜ํ•˜๊ฒŒ ๊ด€๋ จ์„ฑ์ด ๋†’์•˜๋‹ค. ์ด์ƒ๊ณผ ๊ฐ™์€ ๊ฒฐ๊ณผ์— ๊ธฐ์ดˆํ•˜์—ฌ ๋‹ค์Œ๊ณผ ๊ฐ™์ด ์ œ์–ธํ•œ๋‹ค. ์ฒซ์งธ, ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์€ ๋ณด๊ฑด์ธ๋ ฅ์˜ ์ ๊ทน์ ์ธ ์ง€์—ญ์‚ฌํšŒ ํ™œ๋™์„ ์ „์ œ๋กœ ํ•˜๋Š” ๊ฒƒ์ด๋ฏ€๋กœ ๊ธฐ์กด ์ธ๋ ฅ์„ ๊ฐœ๋ฐœํ•˜์—ฌ ์งˆ์ ์ธ ์‚ฌ์—…์„ ์ˆ˜ํ–‰ํ•˜๊ฒŒ ํ•˜์—ฌ์•ผ ํ•  ๊ฒƒ์ด๋ฉฐ ๊ทผ๋ฌดํ•˜๋ฉด์„œ ์ž๊ฒฉ์„ ์ทจ๋“ํ• ์ˆ˜ ์žˆ๋Š” ์ œ๋„์  ๋ณด์™„์ด ์ •์ฑ…์—์„œ ๊ณ ๋ ค๋˜์–ด์•ผ ํ•  ๊ฒƒ์ด๋‹ค. ๋‘˜์งธ, ์ง€์—ญ์‚ฌํšŒ ๊ธฐ์ดˆ์ง„๋‹จ, ๊ด€๋ จ๋ถ€์„œ์™€์˜ ํ˜‘์กฐ ๋ฐ ํƒ€ ๊ธฐ๊ด€๊ณผ์˜ ์—ฐ๊ณ„๋ง ํ˜•์„ฑ, ํƒ€ ์ „๋ฌธ์ง์ข…๊ณผ์˜ ํ˜‘๋ ฅ, ํ™˜์ž์˜ ์กฐ๊ธฐ๋ฐœ๊ฒฌ ๋ฐ ๋Œ€์ƒ์ž์— ๋Œ€ํ•œ ์ถ”ํ›„๊ด€๋ฆฌ, ์ฃผ๋ฏผ์˜ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—… ์ฐธ์—ฌ ๋ฐ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ๋Œ€ํ•œ ํ‰๊ฐ€, ์ง€์—ญยท์ธ๊ตฌยท๋ฉด์ ์„ ๊ณ ๋ คํ•œ ๋Œ€์ƒ์ธ๊ตฌ ๋ถ„๋‹ด ๋“ฑ์˜ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—… ์—…๋ฌด๋ฅผ ๊ฐœ์„ ํ•˜์—ฌ์•ผ ํ•  ๊ฒƒ์ด๋‹ค. ์…‹์งธ, ์ง€์—ญ๋ณด๊ฑด๊ณผ๋ฅผ ์‹ ์„คํ•˜์—ฌ์•ผ ํ•  ๊ฒƒ์ด๋ฉฐ ๊ด€๋ฆฌ์ž์˜ ๊ด€์‹ฌ๋„๊ฐ€ ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์— ์ค‘์š”ํ•˜๊ฒŒ์˜ํ–ฅ์„ ๋ฏธ์น˜๋ฏ€๋กœ ๋‹ด๋‹น ๊ณผ์žฅ๊ธ‰ ์ด์ƒ์˜ ๊ด€๋ฆฌ์ž๋Š” ๋™์ผ ์ง์ข…์— ์˜ํ•ด์„œ ์—…๋ฌด ์ง€์‹œยท๊ฐ๋…์„ ๋ฐ›์•„์•ผ ํ•  ๊ฒƒ์ด๋‹ค. ์ด ์—ฐ๊ตฌ์—์„œ ์ œ์‹œ๋œ ๊ฒฐ๊ณผ๋“ค์— ๋น„์ถ”์–ด ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์„ ํšจ์œจ์ ์œผ๋กœ ํ•˜๊ธฐ ์œ„ํ•ด์„œ๋Š” ์ „๋ฌธ์ธ๋ ฅ์˜ ์–‘์„ฑ, ์กฐ์ง์˜ ์žฌ๊ฐœํŽธ, ์˜ˆ์‚ฐ์˜ ํ™•๋ณด๋ฅผ ํ†ตํ•œ ์‹œ์„ค ๋ฐ ์žฅ๋น„์˜ ๋ณด์™„, ์—…๋ฌด์ง€์นจ๊ฐœ๋ฐœ ๋“ฑ์˜์ค€๋น„๊ฐ€ ํ•„์š”ํ•จ์„ ์•Œ ์ˆ˜ ์žˆ์—ˆ์œผ๋ฉฐ ์•ž์œผ๋กœ ์ด ์—ฐ๊ตฌ๋Š” ๋ฐฉ๋ฌธ๊ฐ„ํ˜ธ์‚ฌ์—…์˜ ์ ํ•ฉํ•œ ๋ฐฉ์•ˆ์„ ๋ชจ์ƒ‰ํ•˜๋Š”๋ฐ ์ฐธ๊ณ ์ž๋ฃŒ๋กœ ์ œ์‹œ๋˜์—ˆ์œผ๋ฉด ํ•œ๋‹ค. [์˜๋ฌธ] This study aims to comprehensively grasp the trend of National health policy on the exploitation of medical and health resources and to find out what implications the current budget policy and its effect would give for setting up and enforcing the health policy hereafter. For these purposes, I did a diachronic analysis of the budget under the jurisdiction of the Health and Welfare Affairs, which has been invested with the aim of increasing the number of sickbed of private hospitals as well as of strengthening the function of both private hospitals and public health organizations for the recent five years. And I, also, compared the change in the sickbed number of each of medical facilities and its sickbed occupancy rate with the increased sickbed number through the Special financial resources from the national treasury loans and those from the farming and fishing villagers' tax. The results are as follows: In the first place, the increasing rate of the budget of general account under the jurisdiction of the Health and Welfare Affairs(which is 19.5% in 1996) is higher than that of National budget, and the component ratio of the Special financial resources from the national treasury loans and the farming and fishing villagers' tax to National budget has risen steadily every year. According to the annual change in National financial support for the purpose of exploiting medical and health resources, the budget of general account to improve the facilities of public health organizations and to strengthen their function was abolished in 1994, when the Special financial resources from the farming and fishing villagers' tax were newly- set up. But it was recompiled again with the view of supporting the Health Centers in some urban areas in 1996. Also, in 1996 and 1997, the budget for building private dementia hospitals was drawn up. The budget of the Special financial resources of the national treasury loans was made up mainly to increase the sickbeds of the private hospitals and in 1997, the another budget items were newly drawn up for the construction and extension of special purpose hospitals and the conversion of mental nursing homes into mental nursing hospitals. The 45.9% of the budget of the Special financial resources from the farming and fishing villagers' tax was assigned to public health organizations and the rest, 54.1%, to private hospitals. Secondly, in all hospitals, except such as tuberculous, leprous, and dental hospital, the rate of the sickbed number increased by financing to the total increased sickbed number for the last three years is 80.5%. The 31.1% of the former was given out to six large cities and the 33.6% of it was alloted to Seoul, Inchon and Kyoungki Area and Southern Kyoungsang Area. And the annual change in the allotment of the total sickbed number to each of cities and counties shows that there was more serious regional unbalance in 1996(urban area: 93.3%; county area: 6.7%) than in 1993. Moreover, the 82.3% of the sickbed number increased by financing was in urban area and the 17.7% of it was in county area. Finally, in hospitals and general hospitals, the rate of the sickbed number increased by financing to the increased sickbed number for the last three years in each of cities and Provinces is as follows: 445.7% in Southern Cheonla Province; 321.0% in Northern Kyoungsang Province; 199.7% in Kwangju Extensive City; 196.8% in Northern Chungchong Province. Although they are all over 100%, the 1996 sickbed occupancy rate of these areas was lower than the average. The annual average rate of the whole country and six large cities has diminished. In Southern Kyoungsang Province, Kyoungki Province and Pusan Extensive City, the component rate of the sickbed number of mental hospitals increased by financing is higher than any other areas. And also the occupancy rate is relatively high in comparison with other hospitals. In Chinese medicine hospitals, the 55.3% of the sickbeds increased by financing was alloted to six large cities and the 43.5% was to Seoul, Inchon and Kyoungki Area. But the 1996 sickbed occupancy rate of this Area is lower than the national average rate. The average sickbed occupancy rate of Chinese medicine hospitals, compared with that of other kind of hospitals, was reduced to a very high degree. As we can see in the above results, the project of the Special financial resources from national treasury loans and from the farming and fishing villagers' tax (which was originally intended to achieve the equity of medical services through increasing the sickbed number of private hospitals and reinforcing the function of both private hospitals and public health organizations), in effect, has resulted in the aggravation of the regional maldistribution primarily because the project increased the sickbed without considering its efficiency. Conclusively, to improve the equity of the sickbed number of private hospitals and the efficiency in running the sickbeds of private hospitals, I believe that it's necessary to review the current financial policy critically and to establish the directionality of the future financial policy.restrictio

    Vascularized bone grafts based on gelatin-heparin conjugated cryogels

    No full text
    ํ•™์œ„๋…ผ๋ฌธ (์„์‚ฌ)-- ์„œ์šธ๋Œ€ํ•™๊ต ๋Œ€ํ•™์› : ๊ณต๊ณผ๋Œ€ํ•™ ํ™”ํ•™์ƒ๋ฌผ๊ณตํ•™๋ถ€, 2018. 2. Nathaniel Hwang.A cryogel is a one of the scaffolds which have high porosity with interconnected macropores providing cell compatible microenvironment. In addition, cryogels can be utilized in minimally invasive surgery due to its sponge-like properties, including rapid shape recovery and injectability. Herein, we developed an injectable cryogel by conjugating heparin to gelatin as a vascular endothelial growth factor (VEGF) and fibroblasts carrier for the treatment of ischemic hind limb mouse model. Our gelatin/heparin cryogel showed a mesh-like network dependent on the gelatin concentration, having a different mechanical properties in swelling ratio, interconnected porosity and elasticity. In addition, integrating heparin into cryogel allowed controlled release of VEGF for a long period, leading to a therapeutic effect demonstrated in in vitro endothelial cell angiogenesis study. Also, its sponge-like properties enabled cryogels to be applied as an injectable system with desirable maintenance of cells and proteins after injection. And, as gelatin is one of the natural polymers that have a high biocompatibility, gelatin/heparin cryogel showed high cell loading efficiency and viability without any other treatment. As a result, overall in this study, we optimized the combination of the concentration of gelatin and heparin in aspect of sustainable release of VEGF and injectability. Finally, optimized gelatin/heparin cryogel integrated with VEGF and NIH-3T3 fibroblasts was applied to in vivo ischemic hind limb model and demonstrated its angiogenic potential by improving neovascularization into the cryogel. As utilizing our gelatin/heparin cryogels with human mesenchymal stem cell (hMSCs), we expect to see the therapeutic effect for bone remodeling.1. Introduction 1 2. Experimental section 3 2.1 Preparation of gelatin-heparin cryogels 3 2.2 Characterization of gelatin-heparin cryogels 4 2.3 Rheology test 5 2.4 Heparin detection via alcian blue assay 6 2.5 Synthesis of RITC-heparin conjugated cryogel 6 2.6 Heparin mediated protein release kinetics 7 2.7 HUVEC migration and tube formation assay 7 2.8 Injecatability test 8 2.9 Preparation of cell seeded scaffolds 9 2.10 PicoGreen and live/dead assay 9 2.11 In vivo ischemic hinlimb mouse model 10 2.12 OCT embedding 10 2.13 Histology & immunostaining 11 3. Results and discussion 13 3.1 Fabrication of gelatin/heparin cryogel 13 3.2 Characterization of gelatin/heparin cryogels 14 3.3 Rheological properties of gelatin/heparin cryogels 16 3.4 Heparin conjugated microarchitecture of gelatin/heparin cryogels according to the heparin concentration 17 3.5 Heparin mediated VEGF release kinetics of gelatin/heparin cryogels according to the heparin concentration 18 3.6 In vitro angiogenic response of HUVEC on VEGF dependent on heparin concentration of gelatin/heparin cryogels 20 3.7 Injectability of gelatin/heparin cryogels 21 3.8 Injectable gelatin/heparin cryogel as an effective carrier of NIH-3T3 fibroblasts 23 3.9 Effect of gelatin/heparin cryogels containing VEGF or/and NIH-3T3 fibroblasts on in vivo ischemic hind limb mouse model for neovascularization 24 4. Conclusion 28 REFERENCES 39 ์š”์•ฝ (๊ตญ๋ฌธ์ดˆ๋ก) 47Maste
    corecore